171 related articles for article (PubMed ID: 8536506)
1. Fecal alpha 1-antitrypsin detection of colorectal neoplasia. An evaluation using HemoQuant.
Moran A; Robinson M; Lawson N; Stanley J; Jones AF; Hardcastle JD
Dig Dis Sci; 1995 Dec; 40(12):2522-5. PubMed ID: 8536506
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests.
Ahlquist DA; Wieand HS; Moertel CG; McGill DB; Loprinzi CL; O'Connell MJ; Mailliard JA; Gerstner JB; Pandya K; Ellefson RD
JAMA; 1993 Mar; 269(10):1262-7. PubMed ID: 8437303
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia.
St John DJ; Young GP; McHutchison JG; Deacon MC; Alexeyeff MA
Ann Intern Med; 1992 Sep; 117(5):376-82. PubMed ID: 1503328
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity, specificity, and predictive value of fecal occult blood testing (Hemoccult II) for colorectal neoplasia in symptomatic patients: a prospective study with total colonoscopy.
Niv Y; Sperber AD
Am J Gastroenterol; 1995 Nov; 90(11):1974-7. PubMed ID: 7485003
[TBL] [Abstract][Full Text] [Related]
5. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program.
Petrelli N; Michalek AM; Freedman A; Baroni M; Mink I; Rodriguez-Bigas M
Surg Oncol; 1994 Feb; 3(1):27-36. PubMed ID: 8186868
[TBL] [Abstract][Full Text] [Related]
6. Patterns of occult bleeding in asymptomatic colorectal cancer.
Ahlquist DA; McGill DB; Fleming JL; Schwartz S; Wieand HS; Rubin J; Moertel CG
Cancer; 1989 May; 63(9):1826-30. PubMed ID: 2702590
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the efficacy of screening tests in colorectal cancer by faecal occult blood test--own experience.
Kozłowski T; Godlewski D; Biczysko M; Grochowalski M; Nelke M; Paszkowski J; Borejsza-Wysocki M; Krokowicz L; Krokowicz P; Banasiewicz T; Drews M
Pol Przegl Chir; 2011 Aug; 83(8):411-23. PubMed ID: 22166714
[TBL] [Abstract][Full Text] [Related]
8. The case for population-based screening for colorectal cancer.
Schoen RE
Nat Rev Cancer; 2002 Jan; 2(1):65-70. PubMed ID: 11902587
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
10. Colonoscopy: a review of its yield for cancers and adenomas by indication.
Rex DK
Am J Gastroenterol; 1995 Mar; 90(3):353-65. PubMed ID: 7872270
[TBL] [Abstract][Full Text] [Related]
11. Measurement of faecal alpha 1-antitrypsin: methodologies and clinical application.
Choudhary S; Gibson PR; Deacon MC; Young GP
J Gastroenterol Hepatol; 1996 Apr; 11(4):311-8. PubMed ID: 8713696
[TBL] [Abstract][Full Text] [Related]
12. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of new occult blood tests for detection of colorectal neoplasia.
St John DJ; Young GP; Alexeyeff MA; Deacon MC; Cuthbertson AM; Macrae FA; Penfold JC
Gastroenterology; 1993 Jun; 104(6):1661-8. PubMed ID: 8500724
[TBL] [Abstract][Full Text] [Related]
14. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
[TBL] [Abstract][Full Text] [Related]
15. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
17. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II.
Kristinsson J; Nygaard K; Aadland E; Barstad S; Sauar J; Hofstad B; Stray N; Stallemo A; Haug B; Ugstad M; Tøn H; Fuglerud P
Digestion; 2001; 64(2):104-10. PubMed ID: 11684824
[TBL] [Abstract][Full Text] [Related]
18. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of a guaiac occult blood test and faecal alpha 1-antitrypsin.
Moran A; Husband D; Jones AF; Asquith P
Gut; 1995 Jan; 36(1):87-9. PubMed ID: 7890241
[TBL] [Abstract][Full Text] [Related]
20. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
